EirGenix (TPE:6589) said the European Medicines Agency (EMA) approved a variation application submitted by its licensing partner Sandoz AG to add a 420 mg vial presentation for its trastuzumab biosimilar HERWENDA (EG12014).
The biosimilar is indicated for the treatment of HER2-positive early and metastatic breast cancer, as well as metastatic gastric cancer, according to a Sunday Taiwan Exchange filing.
EirGenix said the approval follows the launch of the 150 mg presentation in Slovakia and supports preparations for a broader commercial rollout across the European Union.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments